Apellis Pharmaceuticals, a biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the control of the complement system, announced its plans to develop APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies. APL-9, an investigational drug, is a cyclic peptide designed to modulate the complement cascade